Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

EuroTrans wants to go public on the stock exchange of a friendly country

2/6/24 EUTR

EuroTrans plans in 2024 to open at least 35 electric refueling stations

2/6/24 EUTR

M.Video marketplace doubles turnover and number of sellers

2/6/24 MVID

PhosAgro increased output of agrochemical products

2/6/24 PHOR

En+ discusses production of Chinese wind turbines

2/6/24 ENPG

VKontakte has set a record for reaching the Russian population

2/6/24 VKCO

Novatek to open an office in China to market LNG

2/6/24 NVTK

Aeroflot expects passenger traffic to grow by 6%

2/6/24 AFLT

Samolet became the largest participant of the project - an analog of Moscow-City

2/6/24 SMLT

Segezha Group increased plywood production by 40%

2/6/24 SGZH